Background
A global HIV-1 vaccine will need to induce broadly reactive immune responses against conserved HIV-1 regions. It is currently unclear how best to elicit these responses by vaccination. We therefore compared the immunogenicity of a bivalent full-length HIV-1 Gag/Pol/Env mosaic vaccine, a trivalent full-length HIV-1 Gag/Pol/Env mosaic vaccine, and a bivalent mosaic vaccine containing only conserved HIV-1 Gag/Pol/Env epitopes in rhesus monkeys.
Methods
We immunized 18 rhesus monkeys with rAd35 (prime) and rAd26 (boost) vectors expressing bivalent full-length (N=6), trivalent full-length (N=6), or bivalent conservedregion-only (N=6) HIV-1 Gag/Pol/Env mosaic immunogens. We assessed HIV-1-specific and conserved-regionspecific cellular immune responses by ELISPOT using global PTE and vaccine-matched peptides. Responses were mapped to individual epitopes and were identified as CD4+ or CD8+ through cell-depletion assays. Comparisons were performed by Wilcoxon rank-sum tests.
Results
There was no difference in the breadth of HIV-1-specific T lymphocyte responses elicited by the bivalent and trivalent full-length mosaic vaccines (P=.686). However, the bivalent full-length vaccine generated a greater breadth of HIV-1-specific CD8+ T lymphocyte responses than the conserved-region-only vaccine (P=.007). The bivalent full-length vaccine also generated equivalent breadth of CD8+ T lymphocyte responses to conserved HIV-1 epitopes compared to the conserved-region-only vaccine (P=1.000), and surprisingly, the responses generated by the full-length vaccine to conserved HIV-1 epitopes were greater in magnitude than those generated by the conserved-region-only vaccine (P=.008).
Conclusion
These data demonstrate that an HIV-1 mosaic vaccine expressing full-length antigens elicited greater responses to conserved epitopes than a mosaic vaccine expressing only concatenated conserved HIV-1 regions. In addition, the bivalent and trivalent full-length mosaic vaccines generated comparable breadth of HIV-1-specific CD8+ T lymphocyte responses. These results support the clinical development of the bivalent full-length HIV-1 mosaic vaccine.
